EUCTR2012-000334-19-IT进行中（未招募）不适用
Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML)
AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE0 个研究点开始时间: 2012年8月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients aged > 60 years Signed informed consent Morphologically confirmed diagnosis of acute myeloid leukemia by bone marrow aspiration within the past 14 days
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •HIV infection HCV positivity Active second malignancy Diagnosis of relapsed acute promyelocitic leukemia
研究者
相似试验
进行中（未招募）
1 期
Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 MutatioAdult patients (>60) with AML and NPM1 mutation ineligible for intensive chemotherapyEUCTR2010-023409-37-ATniversity Hospital Ulm144
进行中（未招募）
1 期
Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 MutatioAdult patients (>60) with AML and NPM1 mutation ineligible for intensive chemotherapyEUCTR2010-023409-37-DEniversity Hospital Ulm144
已完成
2 期
A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual diseaseCore binding factor acute myeloid leukaemiaCancer - Leukaemia - Acute leukaemiaACTRN12605000152628Australasian Leukaemia and Lymphoma Group53
进行中（未招募）
不适用
Dose-finding study of the substance clofarabine in combination with fixed doses of cytarabine and idarubicine as therapy for patients with acute myeloid leukemia and high risk for treatment failure (CIARA)Patients with acute myeloid leukemia (AML) and high risk for induction failureMedDRA version: 17.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2010-021719-18-DEHannover Medical School
进行中（未招募）
2 期
Multicenter Phase-II-Study with Capecitabine/Trastuzumab as first-line therapy for advanced HER2-overexpressing pancreas carcinomaMedDRA - 10033576C25.9Pancreas, unspecifiedDRKS00000600niversitätsklinikum FreiburgAbteilung Innere Medizin II - Gastroenterologie, Hepatologie, Endokrinologie und Infektiologie17